Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis

Journal of Cellular and Molecular Medicine
Xin Shi, Mingfu Fan

Abstract

Overexpression of KDM2B is frequently occurred in various human solid tumours, and the high levels of KDM2B are associated with tumourigenesis. However, whether and how its activities might be modulated to facilitate tumour progression is still unclear. Immunoprecipitation and immunoblotting were carried out to detect the acetylation of KDM2B. Nucleosomes and mononucleosomes were prepared and the demethylation activity of KDM2B was detected in these two substrates. The effects of KDM2B acetylation on the transcription of target genes, as well as tumour growth and metastasis were then studied. KDM2B was acetylated in osteosarcoma cancer cell lines (MG-63 and HOS). This modification occurred at lysine 758 and catalysed by Tip60. Acetylation of KDM2B decreased the capacity of KDM2B in binding with nucleosomes. KDM2B acetylation diminished its demethylation activity towards nucleosomal substrates rather than towards bulk histone. Besides, acetylation of KDM2B diminished its ability to bind with the promoters of p21 and puma. Moreover, the promoting effects of KDM2B acetylation on tumour cells' proliferation and metastasis, and in vivo tumour growth were dependent on Tip60. KDM2B is acetylated at lysine 758 by Tip60 in human osteosa...Continue Reading

References

Sep 26, 2002·The Journal of Biological Chemistry·Kevin J BittermanDavid A Sinclair
Jul 10, 2003·Cancer Genetics and Cytogenetics·K Al-RomaihJ A Squire
Sep 6, 2005·Molecular Cell·Yu-Jiang ShiYang Shi
Sep 25, 2012·Cellular & Molecular Biology Letters·Paweł Hikisz, Zofia M Kiliańska
Jan 17, 2013·The Journal of Clinical Investigation·Alexandros TzatsosNabeel Bardeesy
Jul 2, 2014·Clinical Orthopaedics and Related Research·Akihiko TakeuchiPatrick P Lin
Nov 29, 2015·The Orthopedic Clinics of North America·Megan E Anderson
Dec 8, 2015·Epigenomics·Gaëlle JudesDominique Bernard-Gallon
Feb 27, 2016·Cell Death and Differentiation·C BassiC Gorrini
Apr 3, 2016·Cold Spring Harbor Perspectives in Biology·James E Audia, Robert M Campbell
Jul 22, 2016·Immunity·Juan LiuXuetao Cao
Feb 7, 2018·Biochimica Et Biophysica Acta. Molecular Cell Research·Nefeli ZacharopoulouChristos Stournaras
Mar 29, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Wenjun YouKun Wang
May 17, 2018·Nature Communications·Terytty Yang LiSheng-Cai Lin
May 18, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Nefeli ZacharopoulouChristos Stournaras
May 31, 2018·Biochemical and Biophysical Research Communications·Chaoyin JiangJianru Xiao
Jul 18, 2018·OncoTargets and Therapy·Xu HanXiaozhou He
Nov 20, 2018·European Journal of Medicinal Chemistry·Appala Venkata Ramana MurthyNicolas Levoin
Nov 26, 2018·The Journal of Investigative Dermatology. Symposium Proceedings·Ming Zhao, Qianjin Lu
Dec 5, 2018·Journal of Experimental & Clinical Cancer Research : CR·Marcella La NoceVirginia Tirino
Dec 6, 2018·Journal of Cellular Physiology·Rana ShafabakhshZatollah Asemi

❮ Previous
Next ❯

Citations

Nov 30, 2019·Archives of Insect Biochemistry and Physiology·Yafei MaZuoming Nie
Aug 17, 2019·Cellular Signalling·Si-Nan SunTao Xu
Dec 29, 2020·Seminars in Cancer Biology·Urszula Oleksiewicz, Marta Machnik

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
ubiquitination
transfection
ELISA
immunoprecipitation
ChIP
sumoylation

Software Mentioned

NIH ImageJ
spss

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.